Alaunos Therapeutics

Alaunos Therapeutics, founded as a clinical-stage cellular immuno-oncology company, is dedicated to treating solid tumors through adoptive TCR-T cell therapy. The company's core mission is to revolutionize cancer treatment by targeting hotspot mutations in tumors. Utilizing their proprietary Sleeping Beauty non-viral transposition technology, Alaunos offers a rapid, flexible, and cost-effective manufacturing process for TCR-T cell therapies. Their robust discovery engine supports the expansion of their TCR library, aiming to provide innovative solutions for patients worldwide.

Notable figures affiliated with Alaunos Therapeutics include leading scientists and industry experts in the field of immuno-oncology. The company has attracted significant investment from prominent venture capital firms and strategic partners, enabling it to advance its clinical programs. Key achievements include the successful development and clinical testing of their TCR-T cell therapies, demonstrating promising safety and efficacy profiles. Overall, Alaunos Therapeutics is making a substantial impact on the oncology landscape by providing cutting-edge treatments for solid tumors, potentially improving outcomes for cancer patients globally.